These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29471464)

  • 41. Reduced cross-protection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine.
    Haveri A; Ikonen N; Julkunen I; Kantele A; Anttila V; Ruotsalainen E; Nohynek H; Lyytikainen O; Savolainen-Kopra C
    Euro Surveill; 2015 Feb; 20(5):21028. PubMed ID: 25677051
    [No Abstract]   [Full Text] [Related]  

  • 42. Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings: A test-negative case-control study in Beijing, China, 2016/17 season.
    Wu S; Pan Y; Zhang X; Zhang L; Duan W; Ma C; Zhang Y; Zhang M; Sun Y; Yang P; Wang Q; Ma J
    Vaccine; 2018 Sep; 36(38):5774-5780. PubMed ID: 30087046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Stockholm County, Sweden, and Finland, January 2017.
    Hergens MP; Baum U; Brytting M; Ikonen N; Haveri A; Wiman Å; Nohynek H; Örtqvist Å
    Euro Surveill; 2017 Feb; 22(8):. PubMed ID: 28251891
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Krajden M; Gubbay JB; Drews SJ; Martineau C; Eshaghi A; Kwindt TL; Bastien N; Li Y
    Clin Infect Dis; 2016 Jul; 63(1):21-32. PubMed ID: 27025838
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
    Kase T; Inoue M; Morikawa S; Kumashiro H; Hiroi S; Nakata K; Ito K; Ishibashi M; Tsuru T; Irie S; Maeda A; Ohfuji S; Fukushima W; Hirota Y
    Vaccine; 2020 Sep; 38(42):6524-6532. PubMed ID: 32873406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
    Valenciano M; Kissling E; Reuss A; Rizzo C; Gherasim A; Horváth JK; Domegan L; Pitigoi D; Machado A; Paradowska-Stankiewicz IA; Bella A; Larrauri A; Ferenczi A; ; Lazar M; Pechirra P; Korczyńska MR; Pozo F; Moren A;
    Euro Surveill; 2016; 21(7):pii=30139. PubMed ID: 26924024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation.
    Gouma S; Furey C; Santos JJS; Parkhouse K; Weirick M; Muramatsu H; Pardi N; Fan SHY; Weissman D; Hensley SE
    J Virol; 2023 Jan; 97(1):e0172322. PubMed ID: 36533954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
    Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
    J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Late season interim estimates of influenza vaccine effectiveness reliably predict end of season estimates in Victoria, Australia, 2007 to 2012.
    Sullivan SG; Kelly H
    Euro Surveill; 2013 Oct; 18(41):20605. PubMed ID: 24135124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estimating Vaccine-Driven Selection in Seasonal Influenza.
    Wen FT; Bell SM; Bedford T; Cobey S
    Viruses; 2018 Sep; 10(9):. PubMed ID: 30231576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
    Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
    J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influenza vaccine effectiveness in Italy: Age, subtype-specific and vaccine type estimates 2014/15 season.
    Rizzo C; Bella A; Alfonsi V; Puzelli S; Palmieri AP; Chironna M; Pariani E; Piatti A; Tiberti D; Ghisetti V; Rangoni R; Colucci ME; Affanni P; Germinario C; Castrucci MR
    Vaccine; 2016 Jun; 34(27):3102-3108. PubMed ID: 27154392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influenza vaccine effectiveness against laboratory confirmed influenza in Greece during the 2013-2014 season: a test-negative study.
    Lytras T; Kossyvakis A; Melidou A; Exindari M; Gioula G; Pogka V; Malisiovas N; Mentis A
    Vaccine; 2015 Jan; 33(2):367-73. PubMed ID: 25448097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular epidemiology and evolution of A(H1N1)pdm09 and H3N2 virus during winter 2012-2013 in Beijing, China.
    Fang Q; Gao Y; Chen M; Guo X; Yang X; Yang X; Wei L
    Infect Genet Evol; 2014 Aug; 26():228-40. PubMed ID: 24911284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).
    Valenciano M; Kissling E; Reuss A; Jiménez-Jorge S; Horváth JK; Donnell JM; Pitigoi D; Machado A; Pozo F;
    Vaccine; 2015 Jun; 33(24):2813-22. PubMed ID: 25936723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interim estimates of the effectiveness of the influenza vaccine against A(H3N2) influenza in adults in South Korea, 2016-2017 season.
    Noh JY; Lim S; Song JY; Choi WS; Jeong HW; Heo JY; Lee J; Seo YB; Lee JS; Wie SH; Kim YK; Park KH; Jung SI; Kim SW; Lee SH; Lee HS; Yoon YH; Cheong HJ; Kim WJ
    PLoS One; 2017; 12(5):e0178010. PubMed ID: 28542417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.